Consolidated Sep 2026 quarter revenue up 30%, profit after tax up 57% vs Sep 2025
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated revenue from operations for the quarter ended 30 September 2026 was Rs 31,608.93 lakh, up 30.4% from Rs 24,242.95 lakh in the year-ago quarter; consolidated profit after tax was Rs 3,956.83 lakh, up 57.5% from Rs 2,512.93 lakh. Earnings before interest, tax, depreciation and amortisation improved to 21.4% of revenue from 20.0%. The secretary resigned for personal reasons; his replacement starts 5 November 2026.
Strong sales and profit growth and a higher cash earnings margin may support the stock; the secretary change appears routine.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.